sameAs
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristicsHIV vaccines: an attainable goal?In vivo binding and retention of CD4-specific DARPin 57.2 in macaquesThe BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivityUse of alternate coreceptors on primary cells by two HIV-1 isolatesA binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 usePotent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionPredicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective studyVirus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations.Astrovirus infection in hospitalized infants with severe combined immunodeficiency after allogeneic hematopoietic stem cell transplantation.Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cellsHuman immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodiesPartial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivityImmune senescence: relative contributions of age and cytomegalovirus infectionHigh-throughput sequencing of human immunoglobulin variable regions with subtype identification.Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entryAnalysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-DependentCross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virusHIV-host interactions: vital to the virus and key to its inhibition.In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.HIV-1 replication activates CD4+ T cells with specificities for persistent herpes virusesDelineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Metagenomic sequencing complements routine diagnostics in identifying viral pathogens in lung transplant recipients with unknown etiology of respiratory infectionIn vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.
P50
Q21090521-096F5625-E05A-4FEC-8DFA-146E33B11B51Q22241163-A4E9962D-F794-4A72-B190-AF4F51164060Q27320871-0B81ED1C-CE83-43C0-934F-3E0730A57566Q28140341-69D247AF-6499-4B3C-9F0A-233452D339B9Q28259404-228B1F51-EFC3-4760-BF40-38E65D3B9050Q28344177-8143D541-037A-4F72-B6D4-BD69C0B7384DQ28344746-F150EB52-38F4-4FB5-9534-990F1A809D5DQ28345395-4B1AE1A0-6204-4986-84FC-972CE5005F05Q28766705-71465B52-4675-499E-83F8-43B57ED0E5BFQ33638320-C3858AC1-ADB6-4DA7-80F8-5A87ACA9D3F2Q33782007-DE43B3D4-658D-4BB6-B502-73268A17C009Q33822395-216F429C-AE6C-46AF-9D80-2C18F5F9453FQ33838098-E2BDF581-C974-4729-B6E9-2740AE54A4F2Q33843345-CB9D859D-FEB4-41A4-9E6F-2EA59B4440D5Q33853859-4E7DEF93-2E46-4223-98AC-394629F68247Q33883813-F6000163-C42C-41F4-9D61-96D8C5951023Q34044256-C81CC01F-DF77-482E-804A-2389913CCB26Q34077930-0C9841D1-FEA0-4A61-BD2B-9AACEA2CFEA8Q34212555-44EE0928-3BC0-43BA-A7AE-80CFE0C12D84Q34227596-BD711DA3-B13A-46AC-B1AF-33A3C37B215BQ34229664-22D8F8DA-ECFD-4EDC-B501-7D9EAF085F2BQ34309493-9731465F-215D-4E75-BC16-BAFED395B535Q34332050-B80A4708-CB6C-4116-A614-B92D8AC335C0Q34390507-D10AC849-7C36-4D39-87B3-DD38C76A1F97Q34445962-8A28DEE0-6005-4028-BE7D-FEC2432855ACQ34648499-BCBB6544-BB67-448A-B338-2C8EA0703B87Q34681455-1A8C6B3F-6D1F-47EB-87F6-165E95AB3A71Q34781878-9304CDD0-2C29-476D-A162-552C9763B9F0Q34875765-83B11073-DDBE-4A4C-9AF4-40E570353AE6Q34975941-2C9FA2B5-8AD6-4EBC-BC55-95F3919FD7A3Q35102328-3FD17E01-022E-4535-B852-4203F15E71BDQ35686912-853E97BD-0B53-40D1-B900-D332051B509BQ35849408-8DB726C3-4202-49F2-B9FB-C2FFF16279DAQ35849627-0931F1D2-F0DF-4C4D-A90D-75148344E678Q35883047-0E84D807-F5A6-4AEE-841E-01C0E2C8FE2BQ35883047-66989440-F526-40B0-95DC-BFFEAE9C3AF0Q35947769-60AE8F60-3093-4EEE-9989-3B8BB9F4FEAFQ36039280-EB5EDF15-A3D6-43F8-87DF-DCBC8A740EC5Q36298503-A8603C5E-F24F-4318-B8B8-C98670409B21Q36380118-0DD5BEE5-B4A6-4B01-A4DB-DDE6D6793F26
P50
description
Virologin, HIV-Forscherin
@de
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Alexandra Trkola
@ast
Alexandra Trkola
@de
Alexandra Trkola
@en
Alexandra Trkola
@es
Alexandra Trkola
@nl
Alexandra Trkola
@sl
type
label
Alexandra Trkola
@ast
Alexandra Trkola
@de
Alexandra Trkola
@en
Alexandra Trkola
@es
Alexandra Trkola
@nl
Alexandra Trkola
@sl
prefLabel
Alexandra Trkola
@ast
Alexandra Trkola
@de
Alexandra Trkola
@en
Alexandra Trkola
@es
Alexandra Trkola
@nl
Alexandra Trkola
@sl
P227
P1053
K-2115-2012
P1960
fexUzZkAAAAJ
P21
P214
1169145857131322922663
P227
1089523777
P31
P3829
P496
0000-0003-1013-876X
P569
1965-01-01T00:00:00Z
P735
P7859
viaf-1169145857131322922663